FDANonrulemakingFDA-2019-D-2102

Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations; Draft Guidance for Industry; Availability

RIN

—

Last modified

Sep 9, 2025

Comment window

closed 2563d ago

Association for Accessible Medicines filings

Activity

Association for Accessible Medicines filed 1 comment on this docket between Jul 23, 2019 and Jul 23, 2019. 0 other organizations filed here. The comment window closed 2563d ago.

What Association for Accessible Medicines filed (1)

Jul 23, 2019· Comment from Association for Accessible Medicines (AAM)· FDA-2019-D-2102-0014

Comments from the Association for Accessible Medicines (AAM) and its Biosimilars Council on behalf of our member companies, regarding FDA-2019-D-2102: Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations; Draft Guidance for Industry. Please find full comments enclosed.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (0)

See everyone who commented →

Association for Accessible MedicinesTHIS ORG
1 filing · confidence 97%